ライフサイエンスコーパス: 17beta-oestradiol

1 farct volume was significantly influenced by 17beta-oestradiol.

2 o that observed for ER's endogenous hormone, 17beta-oestradiol.

3 ist) with and without concurrent infusion of 17beta-oestradiol.

4 ry administration of physiological levels of 17beta-oestradiol (0.08 mg/kg/day) in vivo.

5 prague-Dawley rats were ovariectomised and a 17beta-oestradiol (0.25 mg, 21 day release) or placebo p

6 17beta-Oestradiol (1 microM), reported to potentiate BKC

7 pounds four of them being natural (oestriol, 17beta-oestradiol, 17alpha-oestradiol and oestrone), fou

8 that the biologically active metabolites of 17beta-oestradiol, 2-hydroxyoestradiol (2-OHE2 ) and 4-h

9 europrotective benefits previously seen with 17beta-oestradiol after spinal cord injury may be in par

10 the oxytocin precursor gene as biomarker for 17beta oestradiol and dexamethasone treatment in beef ca

11 by 33.5 and 13.3-fold in cattle treated with 17beta oestradiol and dexamethasone, respectively, in co

12 e is a valid marker for detection of illicit 17beta oestradiol and/or dexamethasone use in beef cattl

13 and 16alpha-hydroxytestosterone to oestrone, 17beta-oestradiol and 17beta,16alpha-oestriol, respectiv

14 ng mechanisms of the catecholoestradiols, to 17beta-oestradiol and catecholamines, we observed that c

15 the presence of hormone, most synergize with 17beta-oestradiol and dafachronic acid respectively to i

16 muscle nNOS correlated directly with plasma 17beta-oestradiol and inversely with the magnitude of sy

17 ess breast cancer risk with obesity, data on 17beta-oestradiol and oestrone levels in the breast and

18 ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxife

19 ng of MAPKs involved in catecholoestradiol-, 17beta-oestradiol- and catecholamine-induced endothelial

20 Local infusion of exogenous 17beta-oestradiol augmented endothelial and smooth muscl

21 interaction between peptides and PDIp, with 17beta-oestradiol being the most potent inhibitor.

22 sis of this nonapeptide only in cattle after 17beta oestradiol, but not after dexamethasone or placeb

23 produced by ATP and tamoxifen was blocked by 17beta-oestradiol, but not 17alpha-oestradiol.

24 vented by chronic treatment of OVX rats with 17beta-oestradiol, but not with chronic progesterone or

25 We also found that the 17beta-oestradiol decreased Ca(2+) retention in brain mi

26 ptide were measured in beef cattle receiving 17beta oestradiol, dexamethasone or placebo over a perio

27 We have investigated rapid effects of 17beta-oestradiol (E) on prolactin (PRL) release in vitr

28 Myocytes were incubated +/-17beta-oestradiol (E2 = 1 nm) and INCX was measured on d

29 KEY POINTS: The catechol metabolites of 17beta-oestradiol (E2 beta), 2-hydroxyoestradiol (2-OHE2

30 The impact of 17beta-oestradiol (E2) exposure on autonomic control of

31 we report that in human breast cancer cells 17beta-oestradiol (E2)-bound oestrogen receptor alpha (E

32 17beta-oestradiol establishes an anti-ferroptotic state

33 teroid hormones such as the potent oestrogen 17beta-oestradiol have been less well recognized by the

34 Plasma 17beta-oestradiol in oestradiol and placebo groups was 7

35 f the human Msx-2 homologue was regulated by 17beta-oestradiol in the MCF-7 breast cancer cell line.

36 -treatment with a high physiological dose of 17beta-oestradiol increased infarct volume after permane

37 actors which, on binding the steroid hormone 17beta-oestradiol, interacts with co-activator proteins

38 Intranasally administered 17beta-oestradiol is significantly better than placebo;

39 The dominance of oestrone and loss of 17beta-oestradiol might underlie the increased prevalenc

40 ffects of allopregnanolone, progesterone and 17beta-oestradiol on oxytocin and vasopressin release fr

41 Furthermore, 17beta-oestradiol protected G93A cortical neurons and sp

42 utaneous implantation of a pellet containing 17beta-oestradiol (release rate 5 mg (21 days)-1).

43 s, rats were either ovariectomized and given 17beta-oestradiol replacement (OVXE2) or sham ovariectom

44 In addition, while 17beta-oestradiol replacement at the end of the long-ter

45 nd they provide increased support that early 17beta-oestradiol replacement is critical in preventing

46 An intranasal 17beta-oestradiol spray, S21400, which bypasses such dra

47 ng gonadotropin-releasing hormone analogues, 17beta-oestradiol, testosterone, steroidal antiandrogens

48 nti-inflammatory properties of premenopausal 17beta-oestradiol, the dominant postmenopausal oestrogen

49 in vitro culture system we demonstrate that 17beta-oestradiol treatment (50 nM) is sufficient to inc

50 CA3 hypersensitivity and amyloidogenesis, if 17beta-oestradiol was initiated at the time of ovariecto

51 However, unlike 17beta-oestradiol, which induces proliferation via oestr